palmitoylethanolamide.com.au
HomeResearchInês 2020

A new role for anandamide: defective link between the systemic and skin endocannabinoid systems in hypertrophic human wound healing

Inês B Correia-Sá, Cláudia M Carvalho, Paula V Serrão, Ana I Loureiro, Carlos Fernandes-Lopes, Marisa Marques, Maria A Vieira-Coelho. Sci Rep. 2020;10(1):11134.

Observational studyHumans

Design
Observational study
Subjects
50 patients undergoing body-contouring surgery; 10 (20%) developed hypertrophic scars
Dose used in the study
No palmitoylethanolamide was given; plasma and skin levels were measured
Duration
Follow-up to 3 months after surgery
What was measured
Anandamide, 2-AG, palmitoylethanolamide and oleoylethanolamide in plasma and scar tissue by LC-MS/MS, comparing normal and hypertrophic scars over time

What the authors reported

The study found:

  • Plasma and skin lipid levels did not differ between normal and hypertrophic scar groups.
  • Plasma and skin anandamide correlated in the normal group (r=0.38, p=0.015) but not the hypertrophic group.
  • Anandamide was lower in hypertrophic scar tissue (0.77 vs 1.15 ng/g, p<0.001).
  • Plasma anandamide, PEA and OEA followed a U-shaped time course after surgery; 2-AG rose at 5 days then fell.

Limits of this study

A prospective observational study of 50 surgical patients, with only 10 hypertrophic scars. It describes natural levels, not effects of taking PEA. The authors declare no competing interests.

Source

PubMed 32636441 · doi:10.1038/s41598-020-68058-3

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.